The clinical prognostic factors and treatment outcomes of adult patients with Ewing sarcoma

Jagodzińska-Mucha, Paulina; Ługowska, Iwona; Świtaj, Tomasz; Koseła-Paterczyk, Hanna; Wągrodzki, Michał; Kozak, Katarzyna; Falkowski, Sławomir; Morysiński, Tadeusz; Goryń, Tomasz; Dawidowska, Anna; Rutkowski, Piotr

doi:10.1007/s10147-020-01741-7

Cited by 7 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there were no differences in toxicities between the treatment arms, it is unknown whether older patients had different tolerability of the regimen. More broadly, chemotherapy dose intensity has been identified as a predictor of outcome in several small studies in adults, which supports the idea that further dose intensification by dose compression may have value 22–24 …”

Section: Introductionmentioning

confidence: 58%

“…More broadly, chemotherapy dose intensity has been identified as a predictor of outcome in several small studies in adults, which supports the idea that further dose intensification by dose compression may have value. [22][23][24] Consensus statement Although prospective data supporting the use of interval compressed chemotherapy in an adult patient population with localized ES are limited, existing data suggest that interval compressed dosing is feasible and safe, so should be considered as it may improve outcomes when compared to non-compressed dosing.…”

Section: Consensus Statementmentioning

confidence: 99%

See 1 more Smart Citation

Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board

Gupta

Riedel

Shah

et al. 2023

Cancer

View full text Add to dashboard Cite

Ewing sarcoma (ES) is a malignant tumor of bone and soft tissue that most often occurs in adolescents and young adults. Despite an international coordinated approach, several nuances, discrepancies, and debates remain in defining the standard of care for treating ES. In this review, the authors leverage the expertise assembled by formation of the National Ewing Sarcoma Tumor Board, a multi‐institution, multidisciplinary virtual tumor board that meets monthly to discuss complicated and challenging cases of ES. This report is focused on select topics that apply to the management of patients with newly diagnosed ES. The specific topics covered include indications for bone marrow aspirate and biopsy for initial evaluation compared with fluorodeoxyglucose‐positron emission tomography, the role of interval compressed chemotherapy in patients aged 18 years and older, the role of adding ifosfamide/etoposide to vincristine/doxorubicin/cyclophosphamide for patients with metastatic disease, the data on and role of high‐dose chemotherapy with autologous stem cell transplantation, maintenance therapy, and whole‐lung irradiation. The data referenced are often limited to subgroup analyses and/or compiled from multiple sources. Although not intended to replace the clinical judgement of treating physicians, the guidelines are intended to provide clarity and recommendations for the upfront management of patients with ES.Plain Language Summary Ewing sarcoma is a malignant tumor of bone and soft tissue that most often occurs in adolescents and young adults. For this review, the authors used the experience of the National Ewing Sarcoma Tumor Board, a multi‐institution, multidisciplinary virtual tumor board that meets monthly to discuss complicated and challenging cases of Ewing sarcoma. Although not intended to replace the clinical judgement of treating physicians, the guidelines will focus on the development of consensus statements for the upfront management of patients with Ewing sarcoma.

show abstract

Section: Introductionmentioning

confidence: 58%

Section: Consensus Statementmentioning

confidence: 99%

Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board

Gupta

Riedel

Shah

et al. 2023

Cancer

View full text Add to dashboard Cite

show abstract

“…There are many treatment methods for Ewing sarcoma, including radiotherapy, surgery, chemotherapy, and targeted drug therapy. Ewing sarcoma is sensitive to radiation therapy, and preoperative neoadjuvant radiotherapy can shrink the tumor and reduce the risk of surgery [18,19]. For metastasized tumors, radiotherapy can be used for treatment [20].…”

Section: Discussionmentioning

confidence: 99%

Bibliometric analysis of Ewing sarcoma from 1993 to 2022

2023

View full text Add to dashboard Cite

Background Ewing sarcoma has attracted more attention in recent years but has yet to be bibliometrically analyzed. Hence, this study investigated the trend of Ewing sarcoma over the past 30 years with bibliometric analysis. Methods Original publications related to Ewing sarcoma were obtained from the Science Citation Index Extension (SCI-E), Social Sciences Citation Index (SSCI), and Web of Science Core Collection (WoSCC) between 1993 and 2022. CiteSpace and VOSviewer were used to extract the countries/regions, institutions, authors, journals, references, and keywords involved in this topic to identify and analyze the research hotspots and trends in this field. Results Over the past 30 years (especially in the past five years), the number of articles published on Ewing sarcoma continued to increase, and the most published country was the United States of America (USA). High-frequency keywords included "Ewing sarcoma", "tumor", "family", "bone", "chemotherapy", "expression", "primitive neuroectodermal tumor", "prognostic factors", "children", and "survival rate". According to the analysis of keyword saliency of Ewing sarcoma, we found that "chromosome translocation", "intergroup", "sarcoma", "genomic landscape", and "children oncology group" were emerging research hotspots. The timeline of the cluster map of co-cited literature indicated that the treatment of Ewing sarcoma emerged as a research hotspot. Conclusion Researchers' understanding of Ewing sarcoma has improved dramatically over the past 30 years. At present, the research hotspots of Ewing sarcoma mainly focus on the aspects of "chromosome translocation", "intergroup", and "sarcoma". In addition, the timeline of the cluster map of co-cited literature indicated the emergence of the treatment of Ewing sarcoma as a research hotspot.

show abstract

“…But the patients always suffered from any adverse reactions in the process of treatment. Despite the multimodal treatments, the 5-year survival rate of OSC patients was still far from satisfactory [ 4 , 5 ]. As such, it was necessary to reveal new biomarker for predicting the prognosis of OSC from the perspective of genetics.…”

Section: Introductionmentioning

confidence: 99%

Genomic nursing science revealed the prolyl 4-hydroxylase subunit alpha 2 as a significant biomarker involved in osteosarcoma

Chen,

Han,

Sun

et al. 2024

Heliyon

View full text Add to dashboard Cite

The clinical prognostic factors and treatment outcomes of adult patients with Ewing sarcoma

Cited by 7 publications

References 30 publications

Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board

Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board

Bibliometric analysis of Ewing sarcoma from 1993 to 2022

Genomic nursing science revealed the prolyl 4-hydroxylase subunit alpha 2 as a significant biomarker involved in osteosarcoma

Contact Info

Product

Resources

About